Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2012

01-06-2012 | Preclinical Study

GRB7 is required for triple-negative breast cancer cell invasion and survival

Authors: Orsi Giricz, Verónica Calvo, Stephanie C. Pero, David N. Krag, Joseph A. Sparano, Paraic A. Kenny

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Login to get access

Abstract

Triple-negative breast cancer (TNBC) is a heterogeneous disease that is usually associated with poor prognosis, and frequently associated with the basal-like breast cancer gene expression profile. There are no targeted therapeutic modalities for this disease, and no useful biomarkers. High GRB7 RNA expression levels are associated with an elevated risk of recurrence in patients with operable TNBC treated with standard adjuvant anthracycline and taxane therapy. To determine whether GRB7 is involved in the pathobiology of TNBC, we evaluated the biological effects of GRB7 inhibition in a panel of triple-negative cell lines—MDA-MB-468, MDA-MB-231, HCC70, and T4-2. We found GRB7 inhibition reduced cell motility and invasion of these cell lines and promoted cell death by apoptosis in 3D culture. These data suggest that GRB7 itself, or GRB7-dependent pathways, may prove to be important therapeutic targets in this disease.
Literature
1.
2.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7:122–192PubMed
3.
Sparano JA, Goldstein L, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman L, Martino S, Davidson NE, Kenny PA, Sledge GW, Jr., Gray R (2011) Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple negative breast cancer. Clin Cancer Res. doi:10.​1158/​1078-0432.​CCR-10-3357
4.
5.
Shen TL, Guan JL (2004) Grb7 in intracellular signaling and its role in cell regulation. Front Biosci 9:192–200PubMedCrossRef
6.
7.
8.
Siamakpour-Reihani S, Argiros HJ, Wilmeth LJ, Haas LL, Peterson TA, Johnson DL, Shuster CB, Lyons BA (2009) The cell migration protein Grb7 associates with transcriptional regulator FHL2 in a Grb7 phosphorylation-dependent manner. J Mol Recognit 22:9–17. doi:10.​1002/​jmr.​916 PubMedCrossRef
9.
Pero SC, Oligino L, Daly RJ, Soden AL, Liu C, Roller PP, Li P, Krag DN (2002) Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7. J Biol Chem 277:11918–11926. doi:10.​1074/​jbc.​M111816200 PubMedCrossRef
10.
Tanaka S, Pero SC, Taguchi K, Shimada M, Mori M, Krag DN, Arii S (2006) Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis. J Natl Cancer Inst 98:491–498. doi:10.​1093/​jnci/​djj105 PubMedCrossRef
11.
12.
Briand P, Petersen OW, Van Deurs B (1987) A new diploid nontumorigenic human breast epithelial cell line isolated and propagated in chemically defined medium. In Vitro Cell Dev Biol 23:181–188PubMedCrossRef
13.
Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96PubMedCrossRef
14.
Moyret C, Madsen MW, Cooke J, Briand P, Theillet C (1994) Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522. Exp Cell Res 215:380–385. doi:10.​1006/​excr.​1994.​1355 PubMedCrossRef
15.
Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359–365PubMedCrossRef
16.
Stein D, Wu J, Fuqua S, Roonprapunt C, Yajnik V, D’Eustachio P, Moskow J, Buchberg A, Osborne C, Margolis B (1994) The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J 13:1331–1340PubMed
17.
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, Devries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515–527PubMedCrossRef
18.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef
19.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043. doi:10.​1126/​science.​1141478 PubMedCrossRef
20.
Nadler Y, Gonzalez AM, Camp RL, Rimm DL, Kluger HM, Kluger Y (2010) Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer. Ann Oncol 21:466–473. doi:10.​1093/​annonc/​mdp346 PubMedCrossRef
21.
Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A (2010) Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression. PLoS ONE 5:e9024. doi:10.​1371/​journal.​pone.​0009024 PubMedCrossRef
22.
Ramsey B, Bai T, Hanlon Newell A, Troxell M, Park B, Olson S, Keenan E, Luoh SW (2010) GRB7 protein over-expression and clinical outcome in breast cancer. Breast Cancer Res Treat. doi:10.​1007/​s10549-010-1010-0
23.
van Agthoven T, Veldscholte J, Smid M, van Agthoven TL, Vreede L, Broertjes M, de Vries I, de Jong D, Sarwari R, Dorssers LC (2009) Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 114:23–30. doi:10.​1007/​s10549-008-9969-5 PubMedCrossRef
24.
van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC (2009) Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 27:542–549. doi:10.​1200/​JCO.​2008.​17.​1462 PubMedCrossRef
25.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRef
26.
27.
McIntyre A, Summersgill B, Spendlove HE, Huddart R, Houlston R, Shipley J (2005) Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia 7:1047–1052PubMedCrossRef
28.
Haran M, Chebatco S, Flaishon L, Lantner F, Harpaz N, Valinsky L, Berrebi A, Shachar I (2004) Grb7 expression and cellular migration in chronic lymphocytic leukemia: a comparative study of early and advanced stage disease. Leukemia 18:1948–1950. doi:10.​1038/​sj.​leu.​2403512 PubMedCrossRef
29.
Ambaye ND, Gunzburg MJ, Lim RC, Price JT, Wilce MC, Wilce JA (2010) Benzopyrazine derivatives: A novel class of growth factor receptor bound protein 7 antagonists. Bioorg Med Chem. doi:10.​1016/​j.​bmc.​2010.​10.​030
30.
Yap MY, Wilce MC, Clayton DJ, Perlmutter P, Aguilar MI, Wilce JA (2010) Preparation and crystallization of the Grb7 SH2 domain in complex with the G7–18NATE nonphosphorylated cyclic inhibitor peptide. Acta Crystallogr Sect F Struct Biol Cryst Commun 66:1640–1643. doi:10.​1107/​S174430911004185​0 PubMedCrossRef
31.
32.
Dankort D, Maslikowski B, Warner N, Kanno N, Kim H, Wang Z, Moran MF, Oshima RG, Cardiff RD, Muller WJ (2001) Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer. Mol Cell Biol 21:1540–1551. doi:10.​1128/​MCB.​21.​5.​1540-1551.​2001 PubMedCrossRef
33.
Ajiro M, Nishidate T, Katagiri T, Nakamura Y (2010) Critical involvement of RQCD1 in the EGFR-Akt pathway in mammary carcinogenesis. Int J Oncol 37:1085–1093PubMed
34.
Cailliau K, Perdereau D, Lescuyer A, Chen H, Garbay C, Vilain JP, Burnol AF, Browaeys-Poly E (2005) FGF receptor phosphotyrosine 766 is a target for Grb14 to inhibit MDA-MB-231 human breast cancer cell signaling. Anticancer Res 25:3877–3882PubMed
35.
Kairouz R, Parmar J, Lyons RJ, Swarbrick A, Musgrove EA, Daly RJ (2005) Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. J Cell Physiol 203:85–93. doi:10.​1002/​jcp.​20199 PubMedCrossRef
Metadata
Title
GRB7 is required for triple-negative breast cancer cell invasion and survival
Authors
Orsi Giricz
Verónica Calvo
Stephanie C. Pero
David N. Krag
Joseph A. Sparano
Paraic A. Kenny
Publication date
01-06-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1822-6

Other articles of this Issue 2/2012

Breast Cancer Research and Treatment 2/2012 Go to the issue

Preclinical study

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours

Preclinical Study

Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors

Epidemiology

Increased diagnosis and detection rates of carcinoma in situ of the breast

Clinical Trial

Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results

Letter to the Editor

Germline mutations 657del5 and 643C>T (R215W) in NBN are not likely to be associated with increased risk of breast cancer in Czech women

Brief Report

Mesothelin, a novel immunotherapy target for triple negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits